Anthrax Treatment Market: Market Size & Forecast 2026

Anthrax is a rare but potentially fatal bacterial infection caused by Bacillus anthracis, naturally found in soil and capable of causing disease through cutaneous, inhalational, or gastrointestinal exposure. The global treatment market addresses both post-exposure prophylaxis and active infection management through antibiotics, monoclonal antibody antitoxins, and vaccines. Despite the disease's rarity in most developed nations, the market remains active due to sustained biodefense imperatives and government preparedness programs.

• •Standard treatments include fluoroquinolones, doxycycline, and anthrax antitoxin for severe cases
• •Inhalational anthrax carries the highest mortality rate and requires immediate treatment
• •Market size estimated at approximately $0.45 billion globally in 2025

The primary driver of market growth is sustained government investment in biodefense and biopreparedness, particularly in the United States, where national stockpile programs maintain reserves of anthrax antitoxin and antibiotics. Ongoing concerns about the potential use of anthrax as a bioterrorism agent keep demand steady among public health agencies and military organizations worldwide. Additionally, expanded indications and improved formulations of existing treatments contribute to incremental market expansion.

• •U.S. government biodefense procurement through the Strategic National Stockpile drives a significant portion of demand
• •Bioterrorism threat perception sustains international stockpiling and preparedness spending
• •Approximately 7% annual growth projected through replenishment cycles and new product introductions

North America dominates the anthrax treatment market, largely due to substantial U.S. government procurement through the Strategic National Stockpile and Biomedical Advanced Research and Development Authority contracts. Europe follows, with growing attention to biopreparedness across EU member states, while Asia-Pacific and other regions represent smaller but emerging markets as national biodefense programs develop. Product categories include antibiotics for post-exposure prophylaxis, antitoxins for active disease management, and vaccines for pre-exposure immunization of at-risk populations.

• •North America holds the largest regional share, supported by extensive government stockpile programs
• •Europe's market is expanding with EU civil protection and biodefense initiatives
• •Products span antibiotics, antitoxins, and vaccines across institutional and government channels

Who are the notable companies in the industry?

Elusys Therapeutics markets Anthim (obiltoxaximab), an FDA-approved monoclonal antibody antitoxin used for the treatment and prophylaxis of inhalational anthrax. Meridian Medical Technologies supplies Anthrax Immune Globulin Intravenous (AIGIV) under long-term contracts with the U.S. government. Bavarian Nordic develops and supplies anthrax vaccines to government and institutional customers, while major pharmaceutical companies including Pfizer and Merck produce antibiotics used in standard anthrax treatment protocols.

• •Elusys Therapeutics: Anthim (obiltoxaximab) antitoxin, FDA-approved for inhalational anthrax
• •Meridian Medical Technologies: AIGIV (Anthrax Immune Globulin Intravenous)
• •Bavarian Nordic: Anthrax vaccine supplier for government stockpile programs

What are the recent trends and outlook?

The anthrax treatment market is expected to maintain steady growth through the mid-2020s, supported by continued government funding for biodefense and periodic stockpile replenishment cycles. Development of next-generation antitoxins and combination therapies remains an area of interest, though the commercial incentive for novel products is tempered by the disease's rarity outside of preparedness contexts. Regulatory pathways, including the FDA's Animal Rule for rare and uncommon diseases, shape how new products enter the market through efficacy studies in animal models.

• •Ongoing replacement cycles of stockpiled antitoxin and antibiotics drive repeat government procurement demand
• •Regulatory incentives such as the Animal Rule facilitate development of treatments for rare diseases
• •Market growth projected to continue at approximately 7% annually through 2030